Histopathology and In Situ Hybridisation
Facilitating all aspects of histopathology including processing, embedding, sectioning, histochemical staining, tissue microarray building, immunohistochemistry, in situ hybridisation, whole slide scanning, and image analysis.
The ‘Histocore’ provides routine histological processing, tissue sectioning, immunohistochemistry (IHC), in situ hybridisation (ISH), and whole slide scanning services to Institute researchers (and external users where capacity allows). Histological services include the capability to process tissue samples and cell lines into frozen, paraffin or vibratome formats for sectioning and staining. The Core constructs tissue microarrays (TMAs) for users and trains in the use of Laser Capture Microdissection (LCM). We also offer image analysis services, so can offer a complete end-to-end service if required.

Jo Arnold
Core Facility Manager
Services
Team members
-
Julia Jones
Scientific Manager
-
Jodi Miller
Principal Scientific Associate
-
Jo Heffer
Senior Scientific Associate
-
Cara Brodie
Senior Scientific Associate
-
Elsa Santos
Scientific Associate
-
Rita Carreira
Scientific Associate
-
Caroline Powell
Research Assistant
-
Julia Ponte
Research Assistant
-
Sophie Dickinson
Research Assistant
Related News
See all news-
Single-cell study sheds new light on why ovarian cancer becomes resistant to chemotherapy
11th August 2025
Researchers at the Cancer Research UK Cambridge Institute and Stanford University have mapped how ovarian cancer cells respond to chemotherapy at an unprecedented level of detail, offering new insights into why treatment resistance develops.
Find out more -
New clue discovered for why some cancer drugs fall short
11th July 2025
Hedgehog signalling plays a key role in controlling how immune cells migrate into tumours, a discovery that may explain why some cancer drugs have underperformed in clinical trials.
Read more -
Identifying tumour characteristics to predict immunotherapy response
6th September 2023
Tumour characteristics could be used to predict whether patients with an aggressive subtype of breast cancer are able to respond to immunotherapy.
Find out more